Literature DB >> 15721354

Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity.

Eeva-Marja Rainio1, Helena Ahlfors, Kara L Carter, Marja Ruuska, Sampsa Matikainen, Elliott Kieff, Päivi J Koskinen.   

Abstract

Latent Epstein-Barr virus (EBV) infection is strongly associated with B-cell proliferative diseases such as Burkitt's lymphoma. Here we show that the oncogenic serine/threonine kinases Pim-1 and Pim-2 enhance the activity of the viral transcriptional activator EBNA2. During EBV infection of primary B-lymphocytes, the mRNA expression levels of pim genes, especially of pim-2, are upregulated and remain elevated in latently infected B-cell lines. Thus, EBV-induced upregulation of Pim kinases and Pim-stimulated EBNA2 transcriptional activity may contribute to the ability of EBV to immortalize B-cells and predispose them to malignant growth.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15721354     DOI： 10.1016/j.virol.2005.01.001

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  16 in total

1.  Genome-wide siRNA screen for mediators of NF-κB activation.

Authors:  Benjamin E Gewurz; Fadi Towfic; Jessica C Mar; Nicholas P Shinners; Kaoru Takasaki; Bo Zhao; Ellen D Cahir-McFarland; John Quackenbush; Ramnik J Xavier; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 2.  The emerging regulatory roles of noncoding RNAs in immune function of fish: MicroRNAs versus long noncoding RNAs.

Authors:  Haitham G Abo-Al-Ela
Journal:  Mol Genet Genomics       Date:  2021-04-27       Impact factor: 3.291

Review 3.  PIM kinase (and Akt) biology and signaling in tumors.

Authors:  Noel A Warfel; Andrew S Kraft
Journal:  Pharmacol Ther       Date:  2015-03-05       Impact factor: 12.310

Review 4.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

5.  Proviral integration site 2 is required for interleukin-6 expression induced by interleukin-1, tumour necrosis factor-α and lipopolysaccharide.

Authors:  Jianfei Yang; Xiang Li; Adedayo Hanidu; Tin M Htut; Rosemarie Sellati; Lian Wang; Huiping Jiang; Jun Li
Journal:  Immunology       Date:  2010-10       Impact factor: 7.397

6.  Feedback Loop Regulation between Pim Kinases and Tax Keeps Human T-Cell Leukemia Virus Type 1 Viral Replication in Check.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  J Virol       Date:  2021-11-24       Impact factor: 6.549

7.  PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.

Authors:  L Brault; T Menter; E C Obermann; S Knapp; S Thommen; J Schwaller; A Tzankov
Journal:  Br J Cancer       Date:  2012-06-21       Impact factor: 7.640

8.  Tricyclic Benzo[cd]azulenes selectively inhibit activities of Pim kinases and restrict growth of Epstein-Barr virus-transformed cells.

Authors:  Alexandros Kiriazis; Riitta L Vahakoski; Niina M Santio; Ralica Arnaudova; Sini K Eerola; Eeva-Marja Rainio; Ingo B Aumüller; Jari Yli-Kauhaluoma; Päivi J Koskinen
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

9.  KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA.

Authors:  Fang Cheng; Magdalena Weidner-Glunde; Markku Varjosalo; Eeva-Marja Rainio; Anne Lehtonen; Thomas F Schulz; Päivi J Koskinen; Jussi Taipale; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2009-03-06       Impact factor: 6.823

10.  Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity.

Authors:  Teija L T Aho; Jouko Sandholm; Katriina J Peltola; Yoshiaki Ito; Päivi J Koskinen
Journal:  BMC Cell Biol       Date:  2006-05-09       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.